‘It's Only Just Begun,' Says Andres Sheppard About Tesla Stock
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
It wasn't long before Tesla took its next leap forward: on June 27, the company completed its first fully autonomous vehicle delivery. Imagine a Model Y quietly departing Tesla's Gigafactory, cruising effortlessly through Austin's streets, and parking itself in the customer's driveway without a single human intervention – that's exactly what happened.
Furthermore, the company announced plans last week to ramp up its robotaxi operation in Austin by adding more vehicles and expanding service coverage. As the system matures and local regulations allow, Tesla aims to phase out the in-car safety monitors altogether, ushering in a truly driverless passenger experience.
Looking further ahead, Tesla is already sketching out the next generation of autonomous ride-sharing. In 2026, the automaker plans to roll out its futuristic Cybercab – a purpose-built, fully autonomous vehicle without a steering wheel or pedals.
Cantor analyst Andres Sheppard sees Tesla's latest moves as another powerful signal of the company's strategic edge in the rapidly evolving autonomous vehicle landscape. According to Sheppard, Tesla's focus on expanding its robotaxi services marks a critical step toward solidifying its role as a frontrunner in the competitive ride-sharing market.
'We expect Robotaxi expansion into the Bay Area (in 3Q), followed by Arizona, Nevada and possibly Florida (in 4Q25/2026E), subject to regulatory approvals… Overall, we continue to see Tesla's Robotaxi segment as a software-as-a-service, high-margin model, and we expect TSLA to have the ability to rapidly scale following commercialization. We expect TSLA will capture a leading market share in these industries,' Sheppard opined.
To this end, Sheppard rates TSLA shares an Overweight (i.e., Buy) along with a $355 price target. (To watch Sheppard's track record, click here)
What does the rest of the Street think? Looking at the consensus breakdown, opinions from other analysts are more spread out. 14 Buys, 15 Holds and 8 Sells add up to a Hold (i.e. Neutral) consensus rating. In addition, the $310.65 average price target indicates ~5% downside from current levels. (See TSLA stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
27 minutes ago
- Business Insider
This Is How Apple (AAPL) Is Staying on Trump's Good Side
President Trump has openly said that he wants tech giant Apple (AAPL) to build iPhones in the U.S., but CEO Tim Cook is taking a different path. Instead of agreeing to move final iPhone assembly to the U.S., Cook joined Trump at the White House to announce a $600 billion investment over four years. This doesn't include making iPhones entirely in the U.S., but it highlights Apple's work with American companies that already make important parts like the glass and facial recognition sensors. Still, Cook explained that final assembly will continue to happen elsewhere. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. It is worth noting that the new 'American Manufacturing Program' looks to help U.S. suppliers grow by strengthening Apple's partnerships with them. For example, all cover glass for iPhones and Apple Watches will be made by Corning (GLW) in Kentucky, with Apple investing $2.5 billion in the effort. Apple also extended its deals with Texas-based companies like Coherent (COHR) and Texas Instruments (TXN), and said that it will be buying advanced chips from TSMC's (TSM) Arizona factory, where Apple will be the main customer. In addition, Apple is expanding its U.S. data centers in North Carolina, Iowa, Nevada, and Oregon in order to support artificial intelligence. Although the announcement pleased Trump and boosted Apple's stock, analysts are unsure how much it will really impact Apple's profits. Indeed, Apple hasn't shared exact spending details, and most supplier agreements are confidential. Interestingly, experts believe that the $600 billion figure likely includes regular costs like payroll, Apple TV+ productions, and ongoing supplier payments. As a result, some see this move as a smart way for Apple to stay on Trump's good side and avoid tariffs, without making big changes to its business model. Is Apple a Buy or Sell Right Now? Turning to Wall Street, analysts have a Moderate Buy consensus rating on AAPL stock based on 15 Buys, 12 Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average AAPL price target of $234.93 per share implies 4.1% upside potential.
Business Insider
27 minutes ago
- Business Insider
Nintendo Stock (NTDOF) Stock Jumps on Gamescom 2025 Booth Lineup
Nintendo (NTDOF) stock was up on Friday after the video game company revealed its lineup for Gamescom 2025. The game hardware and software developer will host a mix of first- and third-party games at its Gamescom booth. On the first-party front, attendees will be able to experience Pokemon Legends: Z-A, Metroid Prime 4: Beyond, and a collection of Nintendo GameCube Classics. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Looking at third-party games, Nintendo has chosen some interesting titles to show off on the Switch 2. That includes the long-awaited Hollow Knight: Silksong, Square Enix's (SQNXF) Final Fantasy 7 Remake Intergrade, CD Projekt's (OTGLY) Cyberpunk 2077: Ultimate Edition, Kadokawa (JP:9468) subsidiary FromSoftware's Elden Ring, and several others. Gamescom 2025 will start on August 20 and last through August 24. Attendees can also use their Nintendo Account at the company's booth to redeem 100 Platinum Points on My Nintendo and an exclusive pin. Nintendo Stock Movement Today Nintendo stock was up 3.07% on Friday, extending a 66.38% rally year-to-date. The shares have also increased 79.87% over the past 12 months. The success of the Switch 2, released in early June, has strongly contributed to these stock gains. Nintendo also recently . This was in response to President Donald Trump's increased tariffs. This hasn't affected the price of the Switch 2 yet, but ongoing trade war actions could cause problems for NTDOF stock. Is Nintendo Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Nintendo is Moderate Buy, based on nine Buy, two Hold, and a single Sell rating over the past three months. With that comes an average NTDOF stock price target of $98.61, representing a potential 1.78% upside for the shares.
Business Insider
42 minutes ago
- Business Insider
Pfizer's (PFE) Turnaround Story Fades as Headwinds Approach
Pfizer's (PFE) Q2 earnings show the company is finally moving past the tough comparisons created by its pandemic-era boom. Pfizer reported superb Q2 figures, with significant year-over-year growth in revenue and EPS while also reaffirming its revenue guidance for the year. The positive earnings news pushed the stock up to as high as $25 per share, only briefly, before the bears regained control. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. At the height of COVID-19, the pharma giant enjoyed a massive surge in vaccine and treatment revenue. But as the pandemic faded and routine COVID immunizations declined, year-over-year revenue took a sharp hit. Now, with that chapter largely behind it, Pfizer's top line is regaining momentum, fueled by innovative blockbusters like VYNDAQEL and ELIQUIS. Still, the road ahead isn't without hazards. Loss of patent exclusivity (LoE) on key drugs and looming regulatory shifts could weigh on future performance. With risk and opportunity so closely intertwined, I'm maintaining a Neutral stance on PFE—despite its latest earnings blowout. —a remarkable feat for a company of its size, where each percentage point becomes harder to achieve. But revenue growth only matters if profits keep pace. On that front, Pfizer delivered as well, aided by cost discipline: research & development spending fell 9%, while selling, general, and administrative expenses dropped 8%. The result? Adjusted diluted EPS came in at $0.78, beating expectations by nearly $0.20. That may not sound earth-shattering—until you remember Pfizer has more than 5.6 billion shares outstanding. That kind of beat adds up fast. Growth Drivers: Vyndaqel, Eliquis, and Oncology Lead the Way Pfizer's strong performance is being powered by standout drugs. The VYNDAQEL family—its treatment for transthyretin-mediated amyloidosis cardiomyopathy— jumped 21% year-over-year to $1.615 billion, making it Pfizer's second-largest revenue source. Its top seller, the blood thinner ELIQUIS, grew 6% to over $2 billion in Q2, fueled by rising global demand in the expanding anticoagulant market. While blockbuster IBRANCE is slipping post–loss of exclusivity, Pfizer's Oncology division remains a powerhouse, generating $4.387 billion in Q2—an 11% increase from last year. Navigating the Storm: Patent Cliffs and Pricing Pressures That said, Pfizer has several pressing challenges on the horizon. Multiple key products—including ELIQUIS—face looming patent expirations over the next few years, putting an estimated $17 billion in annual revenue at risk. To put that in perspective, that's more than an entire quarter's worth of sales. The Inflation Reduction Act (IRA) Medicare Part D Redesign is also weighing on U.S. revenue. In fact, without the 'higher impact discounts' tied to the IRA changes, ELIQUIS's Q2 growth would have been even stronger. Adding to the pressure, Pfizer must navigate geopolitical headwinds—such as tariffs—and potential pricing impacts from Most-Favored-Nation policies. Future Growth: Pipeline Catalysts and Strategic Acquisitions Pfizer isn't standing still—it's been navigating the drug lifecycle for decades. With more than 80 programs in its R&D pipeline, including 23 in Phase 3 trials, the company is positioning itself for the next wave of growth. Oncology remains a core focus, bolstered by the $43 billion acquisition of Seagen in 2023, which is projected to generate roughly $20 billion in risk-adjusted revenue by 2030. One closely watched candidate is SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently in development for non-small cell lung cancer (NSCLC) and other indications. While the PD-1/VEGF class is crowded, it carries ambitions of challenging Merck's (MRK) KEYTRUDA in an NSCLC market expected to surpass $40 billion by 2030. PFE Could be a Discounted Opportunity Without a valuation context, the rest is just noise. Pfizer's P/E ratio of 12.5 sits roughly 49% below the Health Care sector average. Yet the stock has lagged badly, delivering -32% returns over the past decade. Its hefty 6.91% dividend yield may look appealing, but investors should weigh it against the company's long history of underperformance. Is PFE a Buy, Sell, or Hold? On Wall Street, Pfizer carries a Moderate Buy consensus rating based on five Buy, 12 Hold, and zero Sell ratings in the past three months. PFE's average price target of $28.73 implies ~18% upside potential over the next twelve months. Earlier this week, Bank of America Securities analyst Tim Anderson reiterated a Hold rating on PFE with a $28 price target. He highlighted that Pfizer's experimental cancer therapy, SSGJ-707, shows promise but will face intense competition even if it clears clinical trials. While acknowledging the stock's conservative valuation and appealing dividend yield, Anderson maintains a neutral stance, citing 'concerns about long-term growth prospects due to upcoming patent expirations and competitive pressures from other pharmaceutical players.' Pfizer's Comeback Faces Tall Hurdles While Pfizer's outlook is improving, there are clear reasons its stock still trades at a discount. The looming loss of exclusivity for blockbuster drugs like ELIQUIS will be difficult to offset, and the Seagen portfolio alone won't come close to replacing the projected $17 billion revenue hit in the near term. Pfizer must not only deliver in the clinic but also compete effectively in the market, all while contending with the ongoing pricing pressure from the Inflation Reduction Act. Given these headwinds, even with solid cost control and short-term revenue gains, I'm maintaining a Neutral stance on PFE until its long-term growth drivers are firmly in place.
